Pierre Sargis Sayad
Chief Medical Officer · FENNEC PHARMACEUTICALS INC.
- 2024
- Oct 13, 2026
- 10
Summary
Latest filing:
Pierre Sargis Sayad is Chief Medical Officer of FENNEC PHARMACEUTICALS INC. (FENC). 10 SEC Form 4 filings on record going back to 2024, most recently on 13 October 2026. Most recent open-market trade: sold $146K of FENC on 1 September 2026. Lifetime open-market sales: $146K.
Recent transactions
11The latest 11 SEC Form 4 transactions reported by Pierre Sargis Sayad.
Trading pattern
InsiderAlpha's records for Pierre Sargis Sayad go back to 2024: 10 primary Form 4 filings, an average of 3.3 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Pierre Sargis Sayad files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Southpoint Capital Advisors LP - $9.71M in FENC purchases and sales in the last 12 months
- Robert Andrade - $884K in FENC purchases and sales in the last 12 months
- Rosty Raykov - $790K in FENC purchases and sales in the last 12 months
- Marco Maria Brughera - $160K in FENC purchases and sales in the last 12 months
- Chris A. Rallis - $59K in FENC purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Pierre Sargis Sayad?
Pierre Sargis Sayad is a corporate insider, tracked as Chief Medical Officer of FENNEC PHARMACEUTICALS INC. (FENC). InsiderAlpha holds 10 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Pierre Sargis Sayad submitted recently?
4 primary Form 4 filings in the last 90 days, covering 1 company.
Has Pierre Sargis Sayad been buying or selling stock?
Recorded transactions: 0 open-market purchases and 1 open-market sale ($146K) across all tracked filings.